123ArticleOnline Logo
Welcome to 123ArticleOnline.com!
ALL >> General >> View Article

Ascentage Pharma & Astrazeneca Partner For Cll Study

Profile Picture
By Author: Ben Gross
Total Articles: 433
Comment this article
Facebook ShareTwitter ShareGoogle+ ShareTwitter Share

Ascentage Pharma, a global biopharmaceutical company focused on developing innovative treatments for cancer, chronic hepatitis B (CHB), and age-related diseases, has announced a significant clinical collaboration with AstraZeneca Investment (China) Co., Ltd. This collaboration is centered around conducting a Phase III study of APG-2575 (lisaftoclax), a Bcl-2 inhibitor developed by Ascentage Pharma, in combination with AstraZeneca's Bruton's tyrosine kinase (BTK) inhibitor, CALQUENCE® (acalabrutinib). The study will focus on treatment-naive patients with first-line chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

This global, multi-center, randomized-controlled, Phase III trial aims to evaluate the effectiveness and safety of lisaftoclax combined with acalabrutinib compared to immunochemotherapy in treatment-naïve CLL/SLL patients.

This collaboration builds on a previous Phase II study conducted in partnership with Acerta Pharma, a subsidiary of AstraZeneca. In that study, the lisaftoclax and acalabrutinib combination demonstrated strong therapeutic potential, with impressive response rates in ...
... patients with CLL/SLL and a favorable safety profile.

CLL/SLL is a common hematologic malignancy affecting adults, particularly in the Western world. In China, it's increasingly prevalent and more aggressive, presenting a significant health threat. Despite advancements in targeted therapies, there's a pressing need for treatments that offer both efficacy and safety.

Lisaftoclax is a novel Bcl-2 selective inhibitor developed by Ascentage Pharma. It's designed to block the antiapoptotic protein Bcl-2, thereby restoring the normal apoptosis process in cancer cells. Acalabrutinib, on the other hand, is a highly selective BTK inhibitor. This partnership represents an essential step toward offering patients in China more effective and safer treatments for hematologic malignancies.

This collaboration signifies a commitment to addressing unmet clinical needs in the field of cancer treatment. Results from ongoing clinical studies suggest that the combination of lisaftoclax and acalabrutinib holds significant therapeutic potential. Both companies are dedicated to advancing this clinical development program to benefit a broader population of patients and bring innovative therapies to the forefront.

In a rapidly evolving field like oncology, partnerships between biopharmaceutical companies are essential for advancing treatments and improving patient outcomes. This collaboration reflects a commitment to innovation and improving the lives of those affected by hematologic malignancies.

More Information : https://www.techdogs.com/tech-news/pr-newswire/ascentage-pharma-and-astrazeneca-enter-into-clinical-collaboration-on-the-registrational-phase-iii-study-of-bcl-2-inhibitor-lisaftoclax-in-combination-with-btk-inhibitor-acalabrutinib-in-treatment-nave-patients-with-first-line-cll-sll

Total Views: 108Word Count: 340See All articles From Author

Add Comment

General Articles

1. Magento Developers Melbourne: Your Trusted Partner For Magento Web Development
Author: themerchantbuddy

2. How Can E-commerce App Development Help Your Business?
Author: Comfygen

3. The Best Baby Cot Mattress For Summer In Australia: Keep Your Baby Cool And Comfortable !
Author: Milari Organics

4. How Might An Amazon Fba Prep Service Center Help You Streamline Your Business?
Author: 3pshipping6

5. Reviving Artisanal Craftsmanship – Why Handmade Products Matter More Than Ever
Author: Chaitanya Kumari

6. What To Look For In A New York Labor And Employment Law Firm
Author: jewellansing792

7. 50 Years Of Long-lasting Performance
Author: Busch Vacuum Solutions

8. Optimize Healthcare Revenue Cycle: Strategies For Financial Success
Author: Albert brown

9. Offres Exclusives Pour Vos Voyages En Inde Du Nord — Économisez Jusqu’à 30% — Réservez Dès Maintenant!
Author: yatika

10. 200-hour Weekend Yoga Teacher Training Course (yttc) In Bengaluru: A Pathway To Mastery In Yoga
Author: Yogakulam Academy

11. Understanding Patient Behavior: The Importance Of Market Research In Healthcare Marketing
Author: Adomantra

12. Ensuring Safety And Privacy: The Advantages Of Close Protection Services In Dubai
Author: Shancy

13. Thermodynamic Steam Traps: A Compact Solution For Maximum Performance
Author: David John

14. Best Accounting Service In California – Mj Financials
Author: maria jeffery

15. Best Astrologer In Hosahalli
Author: Pandith Keshav Das

Login To Account
Login Email:
Password:
Forgot Password?
New User?
Sign Up Newsletter
Email Address: